Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heartflow Inc. Common Stock (HTFL) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance

Heartflow Inc. Common StockTrade
Relay Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Heartflow Inc. Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Heartflow Inc. Common Stock trades at $49.44 (market cap $4.38B), while Relay Therapeutics Inc. Common Stock trades at $17.07 (market cap $3.81B). The key difference: Heartflow Inc. Common Stock and Relay Therapeutics Inc. Common Stock are close in size by market cap, and Heartflow Inc. Common Stock is trading nearer its 52-week high, Relay Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heartflow Inc. Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.

HTFLRLAY
Market Cap
$4.38B$3.81B
Volume
1,454,4201,706,150
Sector
HealthHealth
52-Week High
$52.21$20.75
52-Week Low
$20.49$6.05
Typical Hold Time
0 Days5 Days
Enterprise Value
$4.24B$2.93B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heartflow Inc. Common Stock

No Aura AI signal available yet.

Relay Therapeutics Inc. Common Stock

Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.

Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HTFL
100% Buy0% Sell
Avg holding period · 0 Days
RLAY

No sentiment data available yet.

About Heartflow Inc. Common Stock

HeartFlow, Inc. develops AI-powered software that analyzes coronary CT angiography scans to build personalized 3D heart models for coronary artery disease diagnosis, including its FFRct Analysis, Plaque Analysis, and Roadmap Analysis tools.

Read more on HTFL →

About Relay Therapeutics Inc. Common Stock

Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.

Read more on RLAY →